Status:
NOT_YET_RECRUITING
LTFU for All Cell and Gene Therapy Studies
Lead Sponsor:
AstraZeneca
Conditions:
Hepatocellular Carcinoma
Prostate Cancer
Eligibility:
All Genders
18-130 years
Brief Summary
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Detailed Description
This is a multi-centre and multinational basket study that will monitor the long-term safety and tolerability of cell or gene therapies in participants that have taken part in other AstraZeneca cell o...
Eligibility Criteria
Inclusion
- The participant has received a cell or gene therapy in another AstraZeneca protocol.
- Provision of signed and dated, written informed consent before any study-specific procedures.
Exclusion
- Not applicable
- \-
Key Trial Info
Start Date :
September 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 29 2041
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06194461
Start Date
September 17 2025
End Date
November 29 2041
Last Update
June 27 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States, 85054
2
Research Site
Duarte, California, United States, 91010
3
Research Site
Orange, California, United States, 92868
4
Research Site
San Francisco, California, United States, 94143